• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Peripheral PRP in the Operating Room vs Standard Clinic PRP for the Initial Treatment of PDR.手术室中周边血源性富血小板血浆与标准诊所血源性富血小板血浆用于增殖性糖尿病视网膜病变初始治疗的比较
J Vitreoretin Dis. 2024 Apr 5;8(4):388-393. doi: 10.1177/24741264241245628. eCollection 2024 Jul-Aug.
2
Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy.全视网膜光凝与抗 VEGF 注射治疗增生性糖尿病视网膜病变的初始治疗。
JAMA Ophthalmol. 2024 Oct 1;142(10):972-975. doi: 10.1001/jamaophthalmol.2024.3283.
3
Outcomes of Pars Plana Vitrectomy with Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy Without Retinal Detachment: A Seven-Year Retrospective Study.不伴有视网膜脱离的增生性糖尿病视网膜病变行玻璃体切割联合全视网膜光凝术的疗效:一项七年回顾性研究
Clin Ophthalmol. 2023 Feb 1;17:471-478. doi: 10.2147/OPTH.S400474. eCollection 2023.
4
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.全视网膜光凝或雷珠单抗治疗的眼中与增殖性糖尿病视网膜病变恶化相关的因素
Ophthalmology. 2017 Apr;124(4):431-439. doi: 10.1016/j.ophtha.2016.12.005. Epub 2017 Feb 1.
5
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.视力、玻璃体积血及其他眼部结局:玻璃体切割术与阿柏西普治疗糖尿病视网膜病变玻璃体积血的比较:一项随机临床试验的二次分析。
JAMA Ophthalmol. 2021 Jul 1;139(7):725-733. doi: 10.1001/jamaophthalmol.2021.1110.
6
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的随机临床试验
JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
7
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.抗血管内皮生长因子治疗增生型糖尿病视网膜病变。
Cochrane Database Syst Rev. 2023 Mar 20;3(3):CD008721. doi: 10.1002/14651858.CD008721.pub3.
8
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内雷珠单抗治疗增生性糖尿病视网膜病变的 5 年疗效比较:一项随机临床试验。
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255.
9
Anti-VEGF Injections vs. Panretinal Photocoagulation Laser Therapy for Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis.抗血管内皮生长因子注射与全视网膜光凝激光治疗增殖性糖尿病视网膜病变的系统评价和荟萃分析
Ophthalmol Retina. 2025 Feb;9(2):105-121. doi: 10.1016/j.oret.2024.08.004. Epub 2024 Aug 14.
10
Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.增殖性糖尿病视网膜病变患者进展为玻璃体切割术的情况。
JAMA Ophthalmol. 2024 Jul 1;142(7):662-668. doi: 10.1001/jamaophthalmol.2024.1844.

引用本文的文献

1
Long-Term Cost Analysis of Initial Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Performed in the Operating Room vs the Clinic.手术室与诊所进行的增殖性糖尿病视网膜病变初次全视网膜光凝的长期成本分析
J Vitreoretin Dis. 2025 Jun 13:24741264251346822. doi: 10.1177/24741264251346822.

本文引用的文献

1
Vision-Related Quality of Life and Treatment Satisfaction Following Panretinal Photocoagulation in Diabetic Retinopathy-A Panel Study.糖尿病视网膜病变全视网膜光凝术后的视力相关生活质量和治疗满意度:一项面板研究。
Medicina (Kaunas). 2022 Nov 28;58(12):1741. doi: 10.3390/medicina58121741.
2
Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy.治疗类型和随访丢失与增生性糖尿病视网膜病变牵拉性视网膜脱离的相关性。
JAMA Ophthalmol. 2023 Jan 1;141(1):40-46. doi: 10.1001/jamaophthalmol.2022.4942.
3
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.接受雷珠单抗治疗增生性糖尿病视网膜病变患者的护理失误:一项随机临床试验的事后分析。
JAMA Ophthalmol. 2021 Dec 1;139(12):1266-1273. doi: 10.1001/jamaophthalmol.2021.4103.
4
All Patients Treated for Proliferative Diabetic Retinopathy Need to Be Monitored Carefully over Time for Further Treatment.所有接受增殖性糖尿病视网膜病变治疗的患者都需要长期接受密切监测,以便进行进一步治疗。
Ophthalmology. 2021 Oct;128(10):1458-1459. doi: 10.1016/j.ophtha.2021.07.019.
5
Using an excel spreadsheet to convert Snellen visual acuity to LogMAR visual acuity.使用电子表格将斯内伦视力转换为最小分辨角对数视力。
Eye (Lond). 2020 Nov;34(11):2148-2149. doi: 10.1038/s41433-020-0783-6. Epub 2020 Feb 4.
6
Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.接受全视网膜光凝与玻璃体内抗血管内皮生长因子治疗后随访丢失的增生性糖尿病视网膜病变眼的结局。
Ophthalmology. 2019 Mar;126(3):407-413. doi: 10.1016/j.ophtha.2018.07.027. Epub 2018 Aug 2.
7
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内雷珠单抗治疗增生性糖尿病视网膜病变的 5 年疗效比较:一项随机临床试验。
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255.
8
Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.增生性糖尿病视网膜病变患者行全视网膜光凝或玻璃体内抗 VEGF 注射后的失访分析。
Ophthalmology. 2018 Sep;125(9):1386-1392. doi: 10.1016/j.ophtha.2018.02.034. Epub 2018 Mar 29.
9
Different lasers and techniques for proliferative diabetic retinopathy.用于增殖性糖尿病视网膜病变的不同激光和技术。
Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012314. doi: 10.1002/14651858.CD012314.pub2.
10
Panretinal Photocoagulation Using Short-Pulse Laser Induces Less Inflammation and Macular Thickening in Patients with Diabetic Retinopathy.使用短脉冲激光进行全视网膜光凝在糖尿病视网膜病变患者中引起的炎症和黄斑增厚较少。
J Ophthalmol. 2017;2017:8530261. doi: 10.1155/2017/8530261. Epub 2017 Jul 6.

手术室中周边血源性富血小板血浆与标准诊所血源性富血小板血浆用于增殖性糖尿病视网膜病变初始治疗的比较

Peripheral PRP in the Operating Room vs Standard Clinic PRP for the Initial Treatment of PDR.

作者信息

Feist Jack E, Drummond Sean C, Fuerst Jonathan S, Crosson Jason N, Feist Richard M

机构信息

University of Louisville School of Medicine, Louisville, KY, USA.

University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

出版信息

J Vitreoretin Dis. 2024 Apr 5;8(4):388-393. doi: 10.1177/24741264241245628. eCollection 2024 Jul-Aug.

DOI:10.1177/24741264241245628
PMID:39148573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11323509/
Abstract

To compare the long-term outcomes of standard panretinal photocoagulation (PRP) performed in the operating room (OR) with peripheral PRP performed in the clinic in treatment-naïve patients with proliferative diabetic retinopathy (PDR). Consecutive cases from 2017 to 2022 were retrospectively reviewed. Exclusion criteria included previous PRP, pars plana vitrectomy performed at the time of the initial PRP, PRP performed in another setting within 3 months of the initial treatment, a documented plan for future PRP at the time of the initial treatment, and less than 3 years of follow-up. Negative binomial regressions were used to compare the number of subsequent interventions between the 2 groups and tests to compare the visual acuity (VA) outcomes. Of the 961 eyes of 679 patients screened, 82 eyes of 53 patients met the inclusion criteria. The initial PRP was performed in the OR (OR cohort) in 57 eyes of 38 patients and in the clinic (clinic cohort) in 25 eyes of 15 patients. The OR cohort had a mean of 0.4 subsequent surgeries and 0.8 subsequent PRP treatments and the clinic cohort, 0.8 subsequent surgeries ( < .05) and 1.8 subsequent PRP treatments ( < .05). No significant between-group difference was found in the VA outcomes over the long-term follow-up (mean, 44.2 months). Peripheral PRP performed in the OR resulted in fewer subsequent interventions than standard PRP in the clinic and may afford better control of PDR.

摘要

比较在手术室进行标准全视网膜光凝(PRP)与在诊所进行周边PRP对初治增殖性糖尿病视网膜病变(PDR)患者的长期疗效。回顾性分析2017年至2022年的连续病例。排除标准包括既往接受过PRP、初次PRP时进行过玻璃体切割术、初次治疗后3个月内在其他机构进行过PRP、初次治疗时有未来进行PRP的记录以及随访时间少于3年。采用负二项回归比较两组后续干预的次数,并进行检验以比较视力(VA)结果。在筛查的679例患者的961只眼中,53例患者的82只眼符合纳入标准。38例患者的57只眼在手术室进行初次PRP(手术室队列),15例患者的25只眼在诊所进行初次PRP(诊所队列)。手术室队列平均有0.4次后续手术和0.8次后续PRP治疗,诊所队列有0.8次后续手术(P<0.05)和1.8次后续PRP治疗(P<0.05)。在长期随访(平均44.2个月)中,两组间VA结果无显著差异。在手术室进行周边PRP比在诊所进行标准PRP导致的后续干预更少,可能对PDR有更好的控制。